Intravesical Evans bacille Calmette‐Guérin for carcinoma in situ of the urinary bladder
- 1 June 1994
- journal article
- Published by Wiley in British Journal of Urology
- Vol. 73 (6) , 645-648
- https://doi.org/10.1111/j.1464-410x.1994.tb07549.x
Abstract
Objective To study the long‐term results of a single 8 week course of intravesical Evans bacillus Calmette‐Guérin (BCG) on carcinoma in situ (CIS) of the urinary bladder. Patients and methods This study reports on 43 patients who each received a single 8 week course of intravesical BCG. Results In spite of the good initial complete response rate of 70%, the long‐term follow‐up was disappointing with half the patients either having recurrence or progression of their disease by 2 years. The patients had a close follow‐up protocol with early radical treatment when disease progressed. The cause specific survival at 5 years was 70%. Conclusion We feel that similar future treatment protocols without maintenance treatment are not justified.Keywords
This publication has 8 references indexed in Scilit:
- Outcome in Carcinoma in situ of Bladder Treated with Intravesical Bacille Calmette‐GuérinPublished by Wiley ,1992
- Radio-Immunoassay Detection of Interferon-Gamma in Urine after Intravesical Evans BCG TherapyJournal of Urology, 1990
- HLA—DR Expression by High Grade Superficial Bladder Cancer Treated with BCGBritish Journal of Urology, 1989
- Intravesical Evans Bacille Calmette-Guérin in the Treatment of Carcinomain situBritish Journal of Urology, 1989
- Two Courses of Intravesical Bacillus Calmette-Guerin for Transitional Cell Carcinoma of the BladderJournal of Urology, 1986
- Flat Carcinoma in situ of BladderBritish Journal of Urology, 1975
- BCG and CancerNew England Journal of Medicine, 1974
- Immunotherapy of Cancer: Regression of Tumors after Intralesional Injection of Living Mycobacterium bovisScience, 1971